Edwards Lifesciences (EW) declined 0.3% according to the provided data. Recent news about the company includes positive clinical results for its Sapien TAVR system presented at CRT 2024. Two real-world studies showed the Sapien 3 Ultra Resilia valve demonstrated lower rates of paravalvular leak compared to older models with favorable hemodynamic outcomes. A separate study confirmed smaller Sapien TAVR valves achieved three-year outcomes equivalent to larger valve sizes. Previously, Edwards reported stronger-than-expected Q4 earnings with revenue of 1.57 billion dollars driven by strong TAVR and TMTT sales, which resulted in a 4% share price increase to 78.92 dollars. The company raised EPS guidance and announced new product launches. Analysts have a mean price target of 96.50 dollars.
Read full analysisEdwards Lifesciences (EW) declined 0.3% according to the provided data. Recent news about the company includes positive clinical results for its Sapien TAVR system presented at CRT 2024. Two real-world studies showed the Sapien 3 Ultra Resilia valve demonstrated lower rates of paravalvular leak compared to older models with favorable hemodynamic outcomes. A separate study confirmed smaller Sapien TAVR valves achieved three-year outcomes equivalent to larger valve sizes. Previously, Edwards reported stronger-than-expected Q4 earnings with revenue of 1.57 billion dollars driven by strong TAVR and TMTT sales, which resulted in a 4% share price increase to 78.92 dollars. The company raised EPS guidance and announced new product launches. Analysts have a mean price target of 96.50 dollars.
Edwards Lifesciences is a medical device company specializing in heart valves and hemodynamic monitoring, best known for its TAVR (transcatheter aortic valve replacement) technology used to treat structural heart disease. The company reported $6.07 billion in 2025 sales and recently announced a $500M accelerated share buyback after navigating post-earnings weakness tied to an EPS miss and the FTC's blocking of its $945M JenaValve acquisition. Today's flat trading reflects a pause after a sharp recovery rally rather than any new development.